Two weeks ago, I lost another friend to addiction.
This is the second one this year.
The first was a friend of mine who was a heroin addict and overdosed, after being clean for more than a year.
The second, and most recent, was Nick, who I’ve known for about 20 years.
We’re still waiting on the toxicology report to find out what happened, but I’m certain prescription opioids were involved, as I know he’s been taking them for years.
One of the reasons, I’ve been so enthusiastic about psychedelics lately, is because there’s a mountain of research indicating that some of these psychedelic medicines are very effective at treating addiction.
Perhaps the most well-publicized research came out of Johns Hopkins University, which showed tremendous success in treating smoking addiction with psilocybin therapy.
If you’re unfamiliar, psilocybin is the psychedelic compound produced by “magic mushrooms.” And in this Johns Hopkins study, researchers saw an 80% success rate, which is unheard of in the world of addiction treatments.
The most ‘effective” smoking cessation therapy on the market today boasts a success rate of about 30%. Hardly a “success,” to be sure.
Now this kind of therapy probably wouldn’t have helped Nick, but another therapy that could have is called ibogaine therapy, and it’s helped thousands of people kick some very nasty habits.
It’s also the substance that has some of the richest people in the world investing in the companies creating it.
$42 Billion up for Grabs
There are about a half dozen companies right now that are working in the field of Ibogaine.
Some are creating new forms of medicine, and some are currently administering it in parts of the world where it’s not illegal to do so.
Take Clear Sky Addiction Solutions, for instance. Which currently runs a clinic in Mexico where people from all over the world have traveled to seek treatment for addiction.
The folks running this operation have been working with ibogaine for more than 20 years and they’re the only researchers in history to be granted FDA approval for clinical testing of Ibogaine on patients in the U.S.
To date, Clear Sky has provided 3,400 treatments, boasting a success rate of 95%.
To put that in perspective, Alcoholics Anonymous, which is often considered the vanguard of addiction treatment, has been identified as having a success rate of less than 25%. And according to Lance Dodes, a psychiatry professor from Harvard Medical School, that success rate could be as low as 5%.
I don’t say this to criticize those who have benefited from Alcoholics Anonymous, but it seems that in 2020, we should be able to do better than this.
Also consider Suboxone, which is often used to treat opioid addiction.
Suboxone has a success rate of about 10% and it’s hardly an effective treatment, as it just substitutes one addiction for another. In what universe is a 10% success rate considered a valid success rate, anyway?
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Although more research needs to be done with ibogaine, the fact is, this could be a real game-changer in terms of addiction treatment. And with addiction expected to climb both during and after this pandemic, the demand for better treatment options is going to soar.
Not to sound crass, but Clear Sky is in the perfect place at the perfect time.
In fact, the company is now gearing up for clinical trials this year, and it’s about to expand its operations to Czech Republic, Portugal, and New Zealand, with the ability to treat up to 25,000 patients a year.
And I think that’s figuring conservatively.
Now just to quickly clarify what this treatment is, and how it works, Ibogaine regulates levels of dopamine and serotonin in the brain, which are chemicals associated with pleasure and feelings of well-being. It also blocks and guards dopamine receptors against harmful drugs, such as opioids, for instance.
The great thing about this is that Ibogaine is not another flawed maintenance or substitution therapy. It’s an actual addiction interrupter. It stops it.
This is what I’m talking about when I say things like “game-changing” and “disruptive.”
We’re talking about going from a defective system of therapy which requires decades worth of treatment, to a potentially more effective treatment that simply ends addiction altogether.
If you or anyone you know has battled addiction, the choice here is clear.
Now at the moment, Clear Sky is not publicly-traded.
But there is another Ibogaine company that is.
It’s one of the biggest players in the space, has raised more than $30 million, and is currently conducting clinical trials for an ibogaine treatment that diminishes opioid withdrawals and reduces drug cravings.
Given the state of today’s opioid epidemic, this is a very big deal.
Last year, the worldwide pharmaceutical sales for opioid abuse came in at around $3 billion. That’s billion, with a “B.”
And the total addressable U.S. market for Ibogaine (i.e. –– the U.S. addiction rehab market) is about $42 billion. Again. Billion –– with a “B.”
This particular stock currently trades for less than $0.50 a share. In another three months, I expect to see it trading over $1.20 a share. That would be a gain of 144.8% if you buy it today.
You can read more about this stock, as well as two more psychedelic investments I’m focusing on right now, in my new report, “Three Magic Molecule Picks for Quadruple-Digital Gains.“
Now I know some folks may be hesitant about investing in psychedelics stocks. But let me share this with you…
I currently have three psychedelics stocks in my portfolio. All three have delivered double-digit gains in less than a month, and all three are expected to deliver triple-digit gains by the end of summer, and quadruple-digit gains by this time next year.
To a new way of life and a new generation of wealth…
Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.